The filing is a routine insider notice with minimal market impact. Monitor for any subsequent Form 4 filings to confirm execution, but no material read-through for the stock.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Douglas Kerr filed a Form 144 notice of intent to sell 2,604 shares of Dyne Therapeutics common stock, with an estimated aggregate market value of approximately $43,810. The shares were acquired through restricted stock unit vesting and equity compensation. The sale is small relative to the company's $3.4B market cap and represents a routine insider transaction.
Key Facts
- Director Douglas Kerr filed Form 144 on 2026-11-13 to sell 2,604 shares of common stock.
- Estimated aggregate market value of the proposed sale is $43,810.
- Shares were acquired via restricted stock unit vesting and equity compensation.
- The filing indicates a prior sale of 3,745 shares on 2026-09-04 and 1,290 shares on 2026-09-08.
- The sale is small relative to the company's $3.4B market capitalization.
Financial Impact
Proposed sale of 2,604 shares valued at ~$43,810, representing less than 0.001% of market cap.
Risk Factors
- Insider selling could be perceived negatively if it precedes adverse news, but the small size and director role limit concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001972481-26-000302 |
| Document: 0001972481-26-000302-index.html | 0001972481-26-000302 |
| Document: 0001972481-26-000302.txt | 0001972481-26-000302 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers